SCHEMBL10168328

SCHEMBL10168328

CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.53
▸ NPY4R P50391 9/20 0.51
▸ NPY5R Q15761 6/20 0.51
▸ NPY1R P25929 5/20 0.51
▸ NPY2R P49146 3/20 0.51
▸ TLR2 O60603 1/20 0.49
▸ NMT2 O60551 1/20 0.48
▸ NMT1 P30419 1/20 0.48
▸ PRSS1 P07477 1/20 0.46
▸ FURIN P09958 1/20 0.46
▸ TFPI P10646 1/20 0.46
▸ NPBWR1 P48145 1/20 0.45
▸ SLC6A5 Q9Y345 1/20 0.44
▸ PLA2G10 O15496 1/20 0.43
▸ KISS1R Q969F8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10168777 1.00 RXFP1 (0.53) RXFP1NPY4RNPY5RNPY1RNPY2R
SCHEMBL16976139 0.92 NPY4R (0.58) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL16976140 0.92 NPY4R (0.58) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL16976101 0.92 NPY4R (0.58) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL10168572 0.91 TLR2 (0.54) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL10168609 0.91 TLR2 (0.54) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL10169218 0.91 TLR2 (0.54) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL16509067 0.89 TLR2 (0.54) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL15185866 0.88 NMT1 (0.60) NPY4RNPY5RNPY1RNPY2RTLR2
SCHEMBL16507758 0.88 NPY4R (0.55) RXFP1NPY4RNPY5RNPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028888-A1 APJ RECEPTOR COMPOUNDS ANCHOR THERAPEUTICS, INC. 2012-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028888-A1 APJ RECEPTOR COMPOUNDS APLNR, AP1G1, AP2B1 RXFP1 827/4885NPY4R 1574/4885NPY5R 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback